Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

FR0011472943
Reset filter
Tue, 03.11.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.10.2026       Valneva SE
FR0011472943

Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for travelers by the United Kingdom’s (UK) Commission on Human Medicines (CHM), the UK marketing authorization for IXCHIQ® has been revoked by the Medicines and H...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.10.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 04.09.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.08.2026       Valneva SE
FR0011472943

NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.08.2026       Valneva SE
FR0011472943

Valneva Half-Year 2026 Financial Report ...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.08.2026       Valneva SE
FR0011472943

Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year ended June 30, 2026, provided key corporate updates, and reaffirmed its financial guidance for 2026. The half year financial report, including the co...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Valneva SE
FR0011472943

Déclaration d'actions et de droits de vote - 31 juillet 2026...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.07.2026       Valneva SE
FR0011472943

Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.07.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 25.06.2026       Valneva SE
FR0011472943

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Valneva SE
FR0011472943

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (Franc...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.06.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Valneva SE
FR0011472943

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Valneva SE
FR0011472943

Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key corporate updates, and updated its 2026 financial guidance. The condensed consolidated interim financial results are available on the Company’s websi...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Valneva SE
FR0011472943

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.05.2026       Valneva SE
FR0011472943

Lyon (France), May 6 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Valneva SE
FR0011472943

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Valneva SE
FR0011472943

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 09.04.2026       Valneva SE
FR0011472943

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Valneva SE
FR0011472943

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Valneva SE
FR0011472943

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Valneva SE
FR0011472943

New York, NY et Lyon (France), le 23 mars 2026 – Pfizer Inc. (NYSE: PFE) et Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ont annoncé aujourd’hui des résultats initiaux pour l’essai clinique de Phase 3 VALOR - Vaccine Against Lyme for Outdoor Recreationists - (NCT05477524) portant sur leur candidat vaccin contre la maladie de Lyme, PF-07307405 (LB...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Valneva SE
FR0011472943

Lyon (France), March 18, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its audited consolidated financial results for the year ended December 31, 2025, provided corporate updates and confirmed its financial guidance for 20261. The Company also announced the filing of its annual report on Form 20-...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.03.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Valneva SE
FR0011472943

Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and provided a first outlook for 2026....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.02.2026       Valneva SE
FR0011472943

Lyon (France), February 13, 2026 – Valneva SE  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vac...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.02.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.02.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       Valneva SE
FR0011472943

Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva’s single-shot chikungunya vaccine, IXCHIQ®. Th...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.01.2026       Valneva SE
FR0011472943

Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ®, in the United States, following sus...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.01.2026       Valneva SE
FR0011472943

 Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, Januar...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 31.12.2025       Valneva SE
FR0011472943

Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.12.2025       Valneva SE
FR0011472943

Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 chi...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.12.2025       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Valneva SE
FR0011472943

Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France  as part of the Company’s ongoing efforts to increase operational effectiveness and position Valneva for long-term success. ...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Valneva SE
FR0011472943

Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (mo...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Valneva SE
FR0011472943

Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valn...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Valneva SE
FR0011472943

Immune response successfully improved with second generation vaccine candidate...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.10.2025       Valneva SE
FR0011472943

Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. ...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.10.2025       Valneva SE
FR0011472943

NEW YORK, Oct. 18, 2025/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.10.2025       Valneva SE
FR0011472943

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       Valneva SE
FR0011472943

NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       Valneva SE
FR0011472943

Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharmakon Advisors, LP. An initial tranche of $215 million will be used to repay in full the Company’s...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       Valneva SE
FR0011472943

VALNEVA...
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.10.2025       Valneva SE
FR0011472943

NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Valneva SE
Technical Analysis Termsheets Terminal
Permalink